Month: July 2024

Rectitude Holdings Ltd Announces Fiscal Year ended March 31, 2024 Full Year Financial Results

SINGAPORE, July 29, 2024 (GLOBE NEWSWIRE) — Rectitude Holdings Ltd (the “Company” or “Rectitude”), a Singapore-based provider of safety equipment and related industrial-grade hardware products, today announced its financial results for the full year ended March 31, 2024. Fiscal Year ended March 31, 2024 Full Year Highlights (amounts in US$ unless otherwise noted): Revenues for the fiscal year ended March 31, 2024, in Singapore Dollars, increased 9.86%. Gross profit margin improved to 35.57% of revenues, up 332 basis points. Selling and marketing expenses in Singapore Dollars, increased S$1.32 million. Research and development expenses in Singapore Dollars decreased S$0.01 million. General and administrative expenses in Singapore Dollars, increased S$1.88 million. Net income was $2.49 million, or $0.20 per diluted share, for the...

Continue reading

AMG Reports Financial and Operating Results for the Second Quarter and First Half of 2024

Company reports EPS of $2.26, Economic EPS of $4.67 in the second quarter of 2024 Net income (controlling interest) of $226 million, Economic Net Income (controlling interest) of $343 million in the first half of the year Economic Earnings per share of $10.06 in the first half of the year, increased 17% year-over-year Positive net client cash flows in the second quarter, driven by continued strength in private markets fundraising Repurchased $327 million in common stock, bringing total share repurchases to $477 million in the first half of the year WEST PALM BEACH, Fla., July 29, 2024 (GLOBE NEWSWIRE) — AMG, a strategic partner to leading independent investment management firms globally, today reported its financial and operating results for the second quarter and six months ended June 30, 2024. Jay C. Horgen, President and Chief...

Continue reading

Tilray’s Aphria RX Receives Cannabis Trading License in Germany, Significantly Expanding Commercial Growth Opportunities

NEUMÜNSTER, Germany, July 29, 2024 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global leader in medical cannabis research, cultivation, production, and distribution, today announced that Aphria RX GmbH (“Aphria RX”) has received a trading license, which will allow it to sell and distribute a broad range of medical cannabis products to pharmacies, hospitals, and medical wholesalers throughout Germany. “This milestone of Aphria RX obtaining both its new cultivation license as well as its trading license further expands Tilray’s leadership in medical cannabis research, cultivation, production and distribution in Germany and once again proves our commitment to be one of the most responsible, trusted and market leading cannabis companies in the world with a portfolio of innovative and high-quality...

Continue reading

Glass Lewis Recommends Asensus Surgical Stockholders Vote “FOR” Proposals Relating to Proposed Merger with KARL STORZ

RESEARCH TRIANGLE PARK, N.C., July 29, 2024 (GLOBE NEWSWIRE) — Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, announced today that a leading independent proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that Asensus Surgical stockholders vote “FOR” all proposals relating to the pending merger transaction with KARL STORZ Endoscopy-America, Inc. (“KARL STORZ”). The vote will take place at the Company’s upcoming Special Meeting of Stockholders to be held virtually at 10:00 a.m. Eastern Time on August 7, 2024. Glass Lewis is widely recognized as a leading independent voting and corporate governance advisory firm. Their analysis and recommendations are meaningful for many major institutional investment firms, mutual funds and fiduciaries...

Continue reading

Integra LifeSciences Reports Second Quarter 2024 Financial Results

PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) — Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2024. Second Quarter 2024 Highlights Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston. Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year. Early integration success with the Acclarent ENT acquisition. Announced plans to focus relaunch of SurgiMend® and PriMatrix® at new state-of-the-art manufacturing facility in Braintree, Massachusetts,...

Continue reading

Provident Financial Holdings Reports Fourth Quarter and Fiscal Year 2024 Results

Net Income of $1.95 Million in the June 2024 Quarter Net Interest Margin of 2.74% in the June 2024 Quarter Loans Held for Investment of $1.05 Billion at June 30, 2024, Down 2% from June 30, 2023 Total Deposits of $888.3 Million at June 30, 2024, Down 7% from June 30, 2023 Non-Performing Assets to Total Assets Ratio of 0.20% at June 30, 2024 Non-Interest Expenses Remain Well Controlled RIVERSIDE, Calif., July 29, 2024 (GLOBE NEWSWIRE) — Provident Financial Holdings, Inc. (“Company”), NASDAQ GS: PROV, the holding company for Provident Savings Bank, F.S.B. (“Bank”), today announced earnings for the fourth quarter and fiscal year ended June 30, 2024. The Company reported net income of $1.95 million, or $0.28 per diluted share (on 6.89 million average diluted shares outstanding) for the quarter ended June 30, 2024, up eight percent...

Continue reading

SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors

STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company’s Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. “Martin is a proven industry leader whose experience in developing and delivering novel treatments to patients in need is exceptional,” said Saqib Islam, Chief Executive Officer of SpringWorks. “His expertise in rare diseases and unique perspectives leading multiple Research and Development organizations across the globe will be extremely...

Continue reading

Brown & Brown, Inc. enters into an agreement to acquire Quintes Holding B.V.

DAYTONA BEACH, Fla., July 29, 2024 (GLOBE NEWSWIRE) — J. Scott Penny, chief acquisitions officer of Brown & Brown, Inc. (NYSE:BRO), Aquiline Capital Partners, Gijsbert van de Nieuwegiessen and the management ownership team of Quintes Holding B.V. (“Quintes”), today announced that the parties have entered into an agreement to acquire the Quintes insurance operations. The transaction is expected to close in the fourth quarter of 2024, subject to certain closing conditions, including the receipt of required regulatory approvals for the acquisition. Quintes was founded in 2012 by Gijsbert van de Nieuwegiessen and is one of the largest independent insurance brokers in the Netherlands. Quintes serves approximately 200,000 customers across its three main divisions: broking, MGA and pension business. Headquartered in Waardenburg,...

Continue reading

Correction: Nokia Corporation: Repurchase of own shares on 26.07.2024

Nokia CorporationStock Exchange Release29 July 2024 at 12:00 EET Correction: Nokia Corporation: Repurchase of own shares on 26.07.2024 Correction to Nokia Oyj’s stock exchange release regarding repurchase of own shares on 26 July 2024. In the English version of the release, total weighted average price per share was misreported. Below the corrected release. Espoo, Finland – On 26 July 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code) Number of shares Weighted average price / share, EUR* XHEL 1,385,661 3.53 CEUX 739,517 3.54 BATE – – AQEU – – TQEX – – Total 2,125,178 3.53 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors...

Continue reading

Aktsiaselts Infortar Investor Webinar introducing the results of the Q2 2024

Infortar will organize a webinar for investors on 5 August 2024 at 12:00 (EET) in Estonian and at 14:00 (EET) in English to introduce the second quarter 2024 results. The webinar will be attended by the Managing Director of Infortar Martti Talgre and Head of Investor Relations Kadri Laanvee. The webinar is open to everyone and takes place without registration of participants. The webinar will be hosted on the Microsoft Teams platform. Please note that to participate, no prior registration is required, and no reminder of the webinar will be sent. You can either participate by joining from your web browser or via Microsoft Teams application. When using a mobile device to join the webinar, you first need to download the Microsoft Teams application from either Play Store or App Store, depending on your device’s software. Please join the webinar...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.